Loading chat...
IN SB0015
Bill
AI Summary
Senate Bill 15 Summary
-
Defines cannabidiol as 2-(6-isopropenyl-3-methyl-2-cyclohexen-1-yl)-5-pentyl-1,3-benzenediol for purposes of IC 35-48-4-11 and IC 16-42-28.
-
Establishes an affirmative defense to marijuana possession charges for individuals with a written physician diagnosis of Dravet syndrome or Lennox-Gastaut syndrome, or parents/guardians of children with these diagnoses, if the substance contains not more than 0.3% THC and at least 10% cannabidiol.
-
Requires cannabidiol to be provided either by a wholesale drug distributor approved by the FDA or regulated by the Indiana board of pharmacy, or as part of a clinical trial by a governmental entity or regionally accredited college or university.
-
Provides that the defense labeling and diagnosis requirements do not apply if the substance has been approved by the federal FDA or DEA as a prescription drug and was prescribed accordingly.
-
Grants civil immunity to health care providers if patients possessing cannabidiol are part of a clinical trial by a governmental entity or regionally accredited college or university.
Legislative Description
Cannabidiol for the treatment of epilepsy. Defines "cannabidiol" and provides an affirmative defense to possession of cannabidiol if the person or the person's child has been diagnosed with certain medical conditions, the cannabidiol contains not more than 0.3% THC and at least 10% cannabidiol, and other specified conditions are met. Provides civil immunity for a health care provider if the patient who possesses the cannabidiol is a part of a clinical trial.
Last Action
House advisors appointed: Lehe, Miller D, Schaibley, DeLaney and Klinker
4/10/2017